SSRIs and SNRIs (SRI) in Pregnancy: Effects on the Course of Pregnancy and the Offspring: How Far Are We from Having All the Answers?
Open Access
- 14 May 2019
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (10) , 2370
Abstract
Serotonin has important roles in the development of the brain and other organs. Manipulations of synaptic serotonin by drugs such as serotonin reuptake inhibitors (SRI) or serotonin norepinephrine reuptake inhibitors (SNRI) might alter their development and function. Of interest, most studies on the outcome of prenatal exposure to SRI in human have not found significant embryonic or fetal damage, except for a possible, slight increase in cardiac malformations. In up to a third of newborns exposed to SRI, exposure may induce transient neonatal behavioral changes (poor neonatal adaptation) and increased rate of persistent pulmonary hypertension. Prenatal SRI may also cause slight motor delay and language impairment but these are transient. The data on the possible association of prenatal SRIs with autism spectrum disorder (ASD) are inconsistent, and seem to be related to pre-pregnancy treatment or to maternal depression. Prenatal SRIs also appear to affect the hypothalamic hypophyseal adrenal (HPA) axis inducing epigenetic changes, but the long-term consequences of these effects on humans are as yet unknown. SRIs are metabolized in the liver by several cytochrome P450 (CYP) enzymes. Faster metabolism of most SRIs in late pregnancy leads to lower maternal concentrations, and thus potentially to decreased efficacy which is more prominent in women that are rapid metabolizers. Studies suggest that the serotonin transporter SLC6A4 promoter is associated with adverse neonatal outcomes after SRI exposure. Since maternal depression may adversely affect the child’s development, one has to consider the risk of SRI discontinuation on the fetus and the child. As with any drug treatment in pregnancy, the benefits to the mother should be considered versus the possible hazards to the developing embryo/fetus.Keywords
This publication has 146 references indexed in Scilit:
- Antidepressant exposure in pregnancy and risk of autism spectrum disordersClinical Epidemiology, 2013
- Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdalaPsychoneuroendocrinology, 2013
- Live and Non-Live Pregnancy Outcomes among Women with Depression and Anxiety: A Population-Based StudyPLOS ONE, 2012
- Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort studyBMJ Open, 2012
- Selective Serotonin Reuptake Inhibitors in Human Pregnancy: To Treat or Not to Treat?Obstetrics and Gynecology International, 2011
- Use of antidepressants during pregnancy and the risk of spontaneous abortionCanadian Medical Association Journal, 2010
- Antidepressant Use During Pregnancy and the Risk of Preterm Delivery and Fetal Growth RestrictionJournal of Clinical Psychopharmacology, 2009
- Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancyAmerican Journal of Obstetrics and Gynecology, 2009
- Risk Factors for Development of Depression and PsychosisAnnals of the New York Academy of Sciences, 2009
- Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational studyBritish Journal of Clinical Pharmacology, 2008